AI-Driven Pathology Reporting Software: How Voicebrook Automates Your Lab | Voicebrook

Voicebrook is redefining the future of pathology reporting through thoughtful application of Generative AI (GenAI). Our suite of AI-powered features exemplifies our commitment to providing innovative solutions that streamline workflows, reduce errors, and enhance reporting accuracy—all while adapting to the real-world needs of pathologists and laboratory staff. 

Read on to learn more about our newest AI features in VoiceOver PRO: DraftDiagnosis, Draft Procedure Line, and No Pause Biopsy.

Streamlining Diagnoses with DraftDiagnosis

DraftDiagnosis represents a significant leap forward in assisting pathologists with summarizing diagnoses in cancer case reports. By automating the data aggregation process, this first-of-its-kind feature significantly boosts pathologists' efficiency. Instead of manually compiling data from cancer checklists to draft a final diagnosis, pathologists only need to input information once. Then the AI-driven DraftDiagnosis feature gathers and summarizes the data for the diagnosis, which the pathologist reviews before submitting the report. 

This approach reduces the risk of human error, saves valuable time, and ultimately leads to improved patient care. With DraftDiagnosis, pathologists can focus on delivering accurate, patient-centered results without the burden of redundant manual tasks.

Click here to see DraftDiagnosis AI in action! 

Simplifying Procedure Line Creation

The procedure line is a small but critical component of pathology reporting, often prone to errors due to repeated manual entry. VoiceOver PRO’s Draft Procedure Line feature eliminates this challenge by automatically generating the procedure line based on the gross description and available AP system data. This ensures accuracy while reducing the cognitive load of reporting, enabling pathologists to focus on clinical decision-making.

This new feature is especially beneficial for pathologists who haven't fully built out their diagnosis templates or don’t include the procedure line in their templates. After the procedure line is generated, the pathologist can then input a diagnosis, streamlining the overall process while maintaining flexibility in critical areas.

Click here to see Draft Procedure Line AI in action!

Efficiency in the Gross Room with No Pause Biopsy

In high-volume grossing environments, time is a precious resource. The No Pause Biopsy AI feature transforms how technicians and pathologists' assistants (PAs) work by enabling them to dictate key variables while the system generates the gross description in a consistent biopsy format. This streamlined approach reduces interruptions, supports efficient workflows, and ensures high-quality output—even during the busiest periods.

Click here to see No Pause Biopsy AI in action!

A Commitment to Innovation

These features are not just tools—they are part of Voicebrook’s larger strategy to continuously advance pathology reporting. Our forward-thinking approach leverages Generative AI to address both routine and complex challenges, providing users with solutions that are accurate, reliable, and adaptable. By automating repetitive tasks and minimizing errors, we empower pathology professionals to dedicate their expertise where it matters most: patient care.

“We see Generative AI as a natural evolution in our mission to enhance the efficiency, accuracy, and impact of pathology reporting,” says CEO Ross Weinstein. “Our AI features are thoughtfully designed to integrate seamlessly into existing workflows, proving that innovation isn’t about reinventing the wheel—it’s about making the journey smoother.”

And this is just the beginning. As we look ahead, Voicebrook remains committed to introducing AI features that meaningfully address real-world challenges. Our goal is to ensure that every enhancement we make supports the needs of pathology professionals while driving the future of patient care.

Learn more about how our AI-powered features are transforming pathology reporting by talking to us.